Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells.
NK cell
NK-92
immunotherapy
serum-free
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jan 2019
10 Jan 2019
Historique:
received:
15
11
2018
revised:
28
12
2018
accepted:
03
01
2019
entrez:
13
1
2019
pubmed:
13
1
2019
medline:
13
1
2019
Statut:
epublish
Résumé
Natural killer (NK) cells stand out as promising candidates for cellular immunotherapy due to their capacity to kill malignant cells. However, the therapeutic use of NK cells is often dependent on cell expansion and activation with considerable amounts of serum and exogenous cytokines. We aimed to develop an expansion protocol for NK-92 cells in an effort to generate a cost-efficient, xeno-free, clinical grade manufactured master cell line for therapeutic applications. By making functional assays with NK-92 cells cultured under serum-free conditions (NK-92
Identifiants
pubmed: 30634595
pii: cancers11010069
doi: 10.3390/cancers11010069
pmc: PMC6356567
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cancerföreningen i Stockholm
ID : 141022
Références
Hum Gene Ther. 1999 May 20;10(8):1359-73
pubmed: 10365666
J Hematother. 1999 Jun;8(3):281-90
pubmed: 10417052
Leukemia. 2000 May;14(5):922-30
pubmed: 10803526
J Hematother Stem Cell Res. 2001 Jun;10(3):369-83
pubmed: 11454312
Leuk Res. 2002 Nov;26(11):1027-33
pubmed: 12363472
Cytotherapy. 2003;5(3):259-72
pubmed: 12850795
Pharmacol Ther. 1992;53(3):355-74
pubmed: 1409851
ALTEX. 2003;20(4):275-81
pubmed: 14671707
J Clin Invest. 2004 Dec;114(11):1612-23
pubmed: 15578093
Cytotherapy. 2008;10(6):625-32
pubmed: 18836917
J Intern Med. 2009 Aug;266(2):154-81
pubmed: 19614820
Cytotechnology. 2010 Jan;62(1):1-16
pubmed: 20373019
Cell Transplant. 2011;20(11-12):1731-46
pubmed: 21669033
Hum Gene Ther. 2012 Oct;23(10):1090-100
pubmed: 22779406
Cytotherapy. 2013 Dec;15(12):1563-70
pubmed: 24094496
Nat Rev Immunol. 2015 Jun;15(6):388-400
pubmed: 25998963
Br J Haematol. 2016 Aug;174(3):473-7
pubmed: 26455823
Front Immunol. 2015 Nov 30;6:605
pubmed: 26648934
Front Immunol. 2017 Mar 31;8:304
pubmed: 28408907
Cytotherapy. 2017 Oct;19(10):1225-1232
pubmed: 28864289
Cancer Immunol Immunother. 2018 Jan;67(1):25-38
pubmed: 28879551
Oncotarget. 2017 Jul 12;8(51):89256-89268
pubmed: 29179517
Am J Cancer Res. 2018 Jun 01;8(6):1083-1089
pubmed: 30034945
J Immunol Res. 2018 Oct 15;2018:4263520
pubmed: 30410941
Front Immunol. 2018 Nov 05;9:2552
pubmed: 30455699
Cancer Res. 1988 Sep 1;48(17):5017-22
pubmed: 3409231
Nature. 1986 Feb 20-26;319(6055):675-8
pubmed: 3951539
In Vitro. 1982 Jun;18(6):576-84
pubmed: 7118138
Leukemia. 1994 Apr;8(4):652-8
pubmed: 8152260
Exp Hematol. 1996 Feb;24(3):406-15
pubmed: 8599969
Biol Blood Marrow Transplant. 1996 May;2(2):68-75
pubmed: 9118301
Blood. 1998 Aug 15;92(4):1374-83
pubmed: 9694726
Clin Cancer Res. 1998 Nov;4(11):2859-68
pubmed: 9829753